¶ = Vaccination according to the routine schedule recommended
§ = Recommended for persons with an additional risk factor for which the vaccine would be indicated
» = Vaccination is recommended, and additional doses may be necessary based on medical condition or vaccine. See Notes.
| = Precaution—vaccine might be indicated if benefit of protection outweighs risk of adverse reaction
± = Contraindicated or not recommended—vaccine should not be administered. *Vaccinate after pregnancy
• = No recommendation/Not applicable
child indications vaccine schedule
Vaccine
Indication
Pregnancy
Immunocompromised status (excluding HIV infection)
For additional information regarding HIV laboratory parameters and use of live vaccines, see the General Best Practice Guidelines for Immunization “Altered Immunocompetence” and Table 4-1 (footnote D).
Severe Combined Immunodeficiency
LAIV4 contraindicated for children 2–4 years of age with asthma or wheezing during the preceding 12 months.
Administer recommended vaccines if immunization history is incomplete or unknown. Do not restart or add doses to vaccine series for extended intervals between doses. When a vaccine is not administered at the recommended age, administer at a subsequent visit. The use of trade names is for identification purposes only and does not imply endorsement by the ACIP or CDC.
Consult relevant ACIP statements for detailed recommendations.
For calculating intervals between doses, 4 weeks = 28 days. Intervals of ≥4 months are determined by calendar months.
Within a number range (e.g., 12–18), a dash (–) should be read as “through.”
Vaccine doses administered ≤4 days before the minimum age or interval are considered valid. Doses of any vaccine administered ≥5 days earlier than the minimum age or minimum interval should not be counted as valid and should be repeated as age-appropriate. The repeat dose should be spaced after the invalid dose by the recommended minimum interval. For further details, see Table 3-1, Recommended and minimum ages and intervals between vaccine doses, in General Best Practice Guidelines for Immunization.
Information on travel vaccination requirements and recommendations is available at https://www.cdc.gov/travel/.
For vaccination of persons with immunodeficiencies, see Table 8-1, Vaccination of persons with primary and secondary immunodeficiencies, in General Best Practice Guidelines for Immunization, and Immunization in Special Clinical Circumstances (In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. Red Book: 2018 report of the Committee on Infectious Diseases. 31st ed. Itasca, IL: American Academy of Pediatrics, 2018:67–111).
For information about vaccination in the setting of a vaccine-preventable disease outbreak, contact your state or local health department.
The National Vaccine Injury Compensation Program (VICP) is a no-fault alternative to the traditional legal system for resolving vaccine injury claims. All routine child and adolescent vaccines are covered by VICP except for pneumococcal polysaccharide vaccine (PPSV23). For more information, see www.hrsa.gov/vaccinecompensation/index.htmlexternal icon.
Dengue Vaccination
Age 9–16 years living in dengue endemic areas AND have laboratory confirmation of previous dengue infection
For contraindications and precautions to dengue vaccination, see Dengue Appendix
Diphtheria, tetanus, and pertussis (DTaP) vaccination
(minimum age: 6 weeks [4 years for Kinrix® or Quadracel®])
5-dose series at age 2, 4, 6, 15–18 months, 4–6 years
Prospectively: Dose 4 may be administered as early as age 12 months if at least 6 months have elapsed since dose 3.
Retrospectively: A 4th dose that was inadvertently administered as early as age 12 months may be counted if at least 4 months have elapsed since dose 3.
Dose 5 is not necessary if dose 4 was administered at age 4 years or older and at least 6 months after dose 3.
Wound management in children less than age 7 years with history of 3 or more doses of tetanus-toxoid-containing vaccine: For all wounds except clean and minor wounds, administer DTaP if more than 5 years since last dose of tetanus-toxoid-containing vaccine. For detailed information, see www.cdc.gov/mmwr/volumes/67/rr/rr6702a1.htm.
For contraindications and precautions to Diphtheria, tetanus, pertussis (DTaP) vaccination, see DTaP Appendix
Haemophilus influenzae type b vaccination
(minimum age: 6 weeks)
ActHIB®, Hiberix®, Pentacel®, or Vaxelis®: 4-dose series (3 dose primary series at age 2, 4, and 6 months, followed by a booster dose* at age 12–15 months)
*Vaxelis® is not recommended for use as a booster dose. A different Hib-containing vaccine should be used for the booster dose.
PedvaxHIB®: 3-dose series (2-dose primary series at age 2 and 4 months, followed by a booster dose at age 12–15 months)
Dose 1 at age 7–11 months: Administer dose 2 at least 4 weeks later and dose 3 (final dose) at age 12–15 months or 8 weeks after dose 2 (whichever is later).
Dose 1 at age 12–14 months: Administer dose 2 (final dose) at least 8 weeks after dose 1.
Dose 1 before age 12 months and dose 2 before age 15 months: Administer dose 3 (final dose) at least 8 weeks after dose 2.
2 doses of PedvaxHIB® before age 12 months: Administer dose 3 (final dose) at age 12–59 months and at least 8 weeks after dose 2.
1 dose administered at age 15 months or older: No further doses needed
Unvaccinated at age 15–59 months: Administer 1 dose.
Previously unvaccinated children age 60 months or olderwho are not considered high risk: Do not require catch-up vaccination
For other catch-up guidance, see Table 2. Vaxelis® can be used for catch-up vaccination in children less than age 5 years. Follow the catch-up schedule even if Vaxelis® is used for one or more doses. For detailed information on use of Vaxelis see www.cdc.gov/mmwr/volumes/69/wr/mm6905a5.htm.
Chemotherapy or radiation treatment:
Age 12–59 months
Unvaccinated or only 1 dose before age 12 months: 2 doses, 8 weeks apart
2 or more doses before age 12 months: 1 dose at least 8 weeks after previous dose
Doses administered within 14 days of starting therapy or during therapy should be repeated at least 3 months after therapy completion.
Hematopoietic stem cell transplant (HSCT):
3-dose series 4 weeks apart starting 6 to 12 months after successful transplant regardless of Hib vaccination history
Anatomic or functional asplenia (including sickle cell disease):
Age 12–59 months
Unvaccinated or only 1 dose before age 12 months: 2 doses, 8 weeks apart
2 or more doses before age 12 months: 1 dose at least 8 weeks after previous dose
Unvaccinated* persons age 5 years or older
1 dose
Elective splenectomy:
Unvaccinated* persons age 15 months or older
1 dose (preferably at least 14 days before procedure)
HIV infection:
Age 12–59 months
Unvaccinated or only 1 dose before age 12 months: 2 doses, 8 weeks apart
2 or more doses before age 12 months: 1 dose at least 8 weeks after previous dose
Unvaccinated* persons age 5–18 years
1 dose
Immunoglobulin deficiency, early component complement deficiency:
Age 12–59 months
Unvaccinated or only 1 dose before age 12 months: 2 doses, 8 weeks apart
2 or more doses before age 12 months: 1 dose at least 8 weeks after previous dose
*Unvaccinated = Less than routine series (through age 14 months) OR no doses (age 15 months or older)
For contraindications and precautions to Haemophilus influenzae type b (Hib) vaccination, see Hib Appendix
Hepatitis A vaccination
(minimum age: 12 months for routine vaccination)
2-dose series (minimum interval: 6 months) at age 12–23 months
Unvaccinated persons through age 18 years should complete a 2-dose series (minimum interval: 6 months).
Persons who previously received 1 dose at age 12 months or older should receive dose 2 at least 6 months after dose 1.
Adolescents age 18 years or older may receive the combined HepA and HepB vaccine, Twinrix®, as a 3-dose series (0, 1, and 6 months) or 4-dose series (3 doses at 0, 7, and 21–30 days, followed by a booster dose at 12 months).
Persons traveling to or working in countries with high or intermediate endemic hepatitis A
(http://www.cdc.gov/travel/)
Infants age 6–11 months: 1 dose before departure; revaccinate with 2 doses, separated by at least 6 months, between age 12–23 months.
Unvaccinated age 12 months or older: Administer dose 1 as soon as travel is considered.
For contraindications and precautions to Hepatitis A (HepA) vaccination, see HepA Appendix
Hepatitis B vaccination
(minimum age: birth)
Mother is HBsAg-negative:
All medically stable infants ≥2,000 grams: 1 dose within 24 hours of birth
Infants <2,000 grams: Administer 1 dose at chronological age 1 month or hospital discharge (whichever is earlier and even if weight is still <2,000 grams).
Mother is HBsAg-positive:
Administer HepB vaccine and hepatitis B immune globulin (HBIG) (in separate limbs) within 12 hours of birth, regardless of birth weight. For infants <2,000 grams, administer 3 additional doses of vaccine (total of 4 doses) beginning at age 1 month.
Test for HBsAg and anti-HBs at age 9–12 months. If HepB series is delayed, test 1–2 months after final dose.
Mother's HBsAg status is unknown:
Administer HepB vaccine within 12 hours of birth, regardless of birth weight.
For infants <2,000 grams, administer HBIG in addition to HepB vaccine (in separate limbs) within 12 hours of birth. Administer 3 additional doses of vaccine (total of 4 doses) beginning at age 1 month.
Determine mother’s HBsAg status as soon as possible. If mother is HBsAg-positive, administer HBIG to infants ≥2,000 grams as soon as possible, but no later than 7 days of age.
3-dose series at age 0, 1–2, 6–18 months (use monovalent HepB vaccine for doses administered before age 6 weeks)
Infants who did not receive a birth dose should begin the series as soon as feasible (see Table 2).
Administration of 4 doses is permitted when a combination vaccine containing HepB is used after the birth dose.
Minimum age for the final (3rd or 4th ) dose: 24 weeks
Minimum intervals: dose 1 to dose 2: 4 weeks / dose 2 to dose 3: 8 weeks / dose 1 to dose 3: 16 weeks (when 4 doses are administered, substitute “dose 4” for “dose 3” in these calculations)
Unvaccinated persons should complete a 3-dose series at 0, 1–2, 6 months.
Adolescents age 11–15 years may use an alternative 2-dose schedule with at least 4 months between doses (adult formulation Recombivax HB® only).
Adolescents age 18 years or older may receive a 2-dose series of HepB (Heplisav-B®) at least 4 weeks apart.
Adolescents age 18 years or older may receive the combined HepA and HepB vaccine, Twinrix®, as a 3-dose series (0, 1, and 6 months) or 4-dose series (3 doses at 0, 7, and 21–30 days, followed by a booster dose at 12 months).
For contraindications and precautions to Hepatitis B (HepB) vaccination, see HepB Appendix
Human papillomavirus vaccination
(minimum age: 9 years)
HPV vaccination routinely recommended at age 11–12 years (can start at age 9 years) and catch-up HPV vaccination recommended for all persons through age 18 years if not adequately vaccinated
2- or 3-dose series depending on age at initial vaccination:
Age 9 –14 years at initial vaccination: 2-dose series at 0, 6–12 months (minimum interval: 5 months; repeat dose if administered too soon)
Age 15 years or older at initial vaccination: 3-dose series at 0, 1–2 months, 6 months (minimum intervals: dose 1 to dose 2: 4 weeks / dose 2 to dose 3: 12 weeks / dose 1 to dose 3: 5 months; repeat dose if administered too soon)
Interrupted schedules: If vaccination schedule is interrupted, the series does not need to be restarted.
No additional dose recommended when any HPV vaccine series has been completed using the recommended dosing intervals.
Immunocompromising conditions, including HIV infection: 3-dose series, even for those who initiate vaccination at age 9 through 14 years.
History of sexual abuse or assault: Start at age 9 years.
Pregnancy: Pregnancy testing not needed before vaccination; HPV vaccination not recommended until after pregnancy; no intervention needed if vaccinated while pregnant
For contraindications and precautions to Human papillomavirus (HPV) vaccination, see HPV Appendix
Influenza vaccination
(minimum age: 6 months [IIV], 2 years [LAIV4], 18 years [recombinant influenza vaccine, RIV4])
Use any influenza vaccine appropriate for age and health status annually:
2 doses, separated by at least 4 weeks, for children age 6 months–8 years who have received fewer than 2 influenza vaccine doses before July 1, 2021, or whose influenza vaccination history is unknown (administer dose 2 even if the child turns 9 between receipt of dose 1 and dose 2)
1 dose for children age 6 months–8 years who have received at least 2 influenza vaccine doses before July 1, 2021
For the 2022–23 season, see the 2022–23 ACIP influenza vaccine recommendations.
Egg allergy, hives only: Any influenza vaccine appropriate for age and health status annually
Egg allergy with symptoms other than hives (e.g., angioedema, respiratory distress) or required epinephrine or another emergency medical intervention: see Appendix listing contraindications and precautions.
Measles, mumps, and rubella vaccination
(minimum age: 12 months for routine vaccination)
2-dose series at age 12–15 months, age 4–6 years
MMR or MMRV may be administered
Note: For dose 1 in children age 12–47 months, it is recommended to administer MMR and varicella vaccines separately. MMRV may be used if parents or caregivers express a preference.
Unvaccinated children and adolescents: 2-dose series at least 4 weeks apart
The maximum age for use of MMRV is 12 years.
Minimum interval between MMRV doses: 3 months
International travel
Infants age 6–11 months: 1 dose before departure; revaccinate with 2-dose series at age 12–15 months (12 months for children in high-risk areas) and dose 2 as early as 4 weeks later.
Unvaccinated children age 12 months or older: 2-dose series at least 4 weeks apart before departure
For contraindications and precautions to Measles, mumps, rubella (MMR), see MMR Appendix
Meningococcal serogroup A, C, W, Y vaccination (minimum age: 2 months [MenACWY-CRM, Menveo], 9 months [MenACWY-D, Menactra], 2 years [MenACWY-TT, MenQuadfi])
2-dose series at age 11–12 years, 16 years
Age 13–15 years: 1 dose now and booster at age 16–18 years (minimum interval: 8 weeks)
Age 16–18 years: 1 dose
Anatomic or functional asplenia (including sickle cell disease), HIV infection, persistent complement component deficiency, complement inhibitor (e.g., eculizumab, ravulizumab) use:
Menveo
Dose 1 at age 2 months: 4-dose series (additional 3 doses at age 4, 6 and 12 months)
Dose 1 at age 3–6 months: 3- or 4- dose series (dose 2 [and dose 3 if applicable] at least 8 weeks after previous dose until a dose is received at age 7 months or older, followed by an additional dose at least 12 weeks later and after age 12 months)
Dose 1 at age 7–23 months: 2-dose series (dose 2 at least 12 weeks after dose 1 and after age 12 months)
Dose 1 at age 24 months or older: 2-dose series at least 8 weeks apart
Menactra
Persistent complement component deficiency or complement inhibitor use:
Age 9–23 months: 2-dose series at least 12 weeks apart
Age 24 months or older: 2-dose series at least 8 weeks apart
Anatomic or functional asplenia, sickle cell disease, or HIV infection:
Age 9–23 months: Not recommended
Age 24 months or older: 2-dose series at least 8 weeks apart
Menactra® must be administered at least 4 weeks after completion of PCV13 series.
MenQuadfi®
Dose 1 at age 24 months or older: 2-dose series at least 8 weeks apart
Travel in countries with hyperendemic or epidemic meningococcal disease, including countries in the African meningitis belt or during the Hajj
(www.cdc.gov/travel/):
Children less than age 24 months:
Menveo® (age 2–23 months)
Dose 1 at age 2 months: 4-dose series (additional 3 doses at age 4, 6 and 12 months)
Dose 1 at age 3–6 months: 3- or 4- dose series (dose 2 [and dose 3 if applicable] at least 8 weeks after previous dose until a dose is received at age 7 months or older, followed by an additional dose at least 12 weeks later and after age 12 months)
Dose 1 at age 7–23 months: 2-dose series (dose 2 at least 12 weeks after dose 1 and after age 12 months)
Menactra® (age 9–23 months)
2-dose series (dose 2 at least 12 weeks after dose 1; dose 2 may be administered as early as 8 weeks after dose 1 in travelers)
Children age 2 years or older: 1 dose Menveo®, Menactra®, or MenQuadfi®
First-year college students who live in residential housing (if not previously vaccinated at age 16 years or older) or military recruits:
1 dose Menveo®,, Menactra®, or MenQuadfi®
Adolescent vaccination of children who received MenACWY prior to age 10 years:
Children for whom boosters are recommended because of an ongoing increased risk of meningococcal disease (e.g., those with complement deficiency, HIV, or asplenia): Follow the booster schedule for persons at increased risk.
Children for whom boosters are not recommended (e.g., a healthy child who received a single dose for travel to a country where meningococcal disease is endemic): Administer MenACWY according to the recommended adolescent schedule with dose 1 at age 11–12 years and dose 2 at age 16 years.
Note: Menactra® should be administered either before or at the same time as DTaP. MenACWY vaccines may be administered simultaneously with MenB vaccines if indicated, but at a different anatomic site, if feasible.
For MenACWY booster doserecommendations for groups listed under “Special situations” and in an outbreak setting and additional meningococcal vaccination information, see www.cdc.gov/mmwr/volumes/69/rr/rr6909a1.htm.
For contraindications and precautions to Meningococcal ACWY (MenACWY)
[MenACWY-CRM (Menveo®); MenACWY-D (Menactra®); MenACWY-TT (MenQuadfi®)], see MenACWY Appendix
Meningococcal serogroup B vaccination
(minimum age: 10 years [MenB-4C, Bexsero®; MenB-FHbp, Trumenba®])
Adolescents not at increased risk age 16–23 years (preferred age 16–18 years) based on shared clinical decision-making:
Bexsero®: 2-dose series at least 1 month apart
Trumenba®: 2-dose series at least 6 months apart; if dose 2 is administered earlier than 6 months, administer a 3rd dose at least 4 months after dose 2.
Note: Bexsero® and Trumenba® are not interchangeable; the same product should be used for all doses in a series.
For MenB booster dose recommendations for groups listed under “Special situations” and in an outbreak setting and additional meningococcal vaccination information, see www.cdc.gov/mmwr/volumes/69/rr/rr6909a1.htm.
For contraindications and precautions to Meningococcal B (MenB)
[MenB-4C (Bexsero®); MenB-FHbp (Trumenba®)], see MenB Appendix
Pneumococcal vaccination
(minimum age: 6 weeks [PCV13], 2 years [PPSV23])
4-dose series at age 2, 4, 6, 12–15 months
1 dose for healthy children age 24–59 months with any incomplete* PCV13 series
* Incomplete series = Not having received all doses in either the recommended series or an age-appropriate catch-up series See Tables 8, 9, and 11 in the ACIP pneumococcal vaccine recommendations (www.cdc.gov/mmwr/pdf/rr/rr5911.pdfpdf icon) for complete schedule details.
Underlying conditions below: When both PCV13 and PPSV23 are indicated, administer PCV13 first. PCV13 and PPSV23 should not be administered during same visit.
3 PCV13 doses: 1 dose PCV13 (at least 8 weeks after any prior PCV13 dose)
Less than 3 PCV13 doses: 2 doses PCV13 (8 weeks after the most recent dose and administered 8 weeks apart)
No history of PPSV23: 1 dose PPSV23 (at least 8 weeks after completing all recommended PCV13 doses)
Age 6–18 years
No history of PPSV23: 1 dose PPSV23 (at least 8 weeks after completing all recommended PCV13 doses)
Cerebrospinal fluid leak, cochlear implant:
Age 2–5 years
Any incomplete* series with:
3 PCV13 doses: 1 dose PCV13 (at least 8 weeks after any prior PCV13 dose)
Less than 3 PCV13 doses: 2 doses PCV13 (8 weeks after the most recent dose and administered 8 weeks apart)
No history of PPSV23: 1 dose PPSV23 (at least 8 weeks after any prior PCV13 dose)
Age 6–18 years
No history of either PCV13 or PPSV23: 1 dose PCV13, 1 dose PPSV23 at least 8 weeks later
Any PCV13 but no PPSV23: 1 dose PPSV23 at least 8 weeks after the most recent dose of PCV13
PPSV23 but no PCV13: 1 dose PCV13 at least 8 weeks after the most recent dose of PPSV23
Sickle cell disease and other hemoglobinopathies; anatomic or functional asplenia; congenital or acquired immunodeficiency; HIV infection; chronic renal failure; nephrotic syndrome; malignant neoplasms, leukemias, lymphomas, Hodgkin disease, and other diseases associated with treatment with immunosuppressive drugs or radiation therapy; solid organ transplantation; multiple myeloma:
Age 2–5 years
Any incomplete* series with:
3 PCV13 doses: 1 dose PCV13 (at least 8 weeks after any prior PCV13 dose)
Less than 3 PCV13 doses: 2 doses PCV13 (8 weeks after the most recent dose and administered 8 weeks apart)
No history of PPSV23: 1 dose PPSV23 (at least 8 weeks after any prior PCV13 dose) and a dose 2 of PPSV23 5 years later
Age 6–18 years
No history of either PCV13 or PPSV23: 1 dose PCV13, 2 doses PPSV23 (dose 1 of PPSV23 administered 8 weeks after PCV13 and dose 2 of PPSV23 administered at least 5 years after dose 1 of PPSV23)
Any PCV13 but no PPSV23: 2 doses PPSV23 (dose 1 of PPSV23 administered 8 weeks after the most recent dose of PCV13 and dose 2 of PPSV23 administered at least 5 years after dose 1 of PPSV23)
PPSV23 but no PCV13: 1 dose PCV13 at least 8 weeks after the most recent PPSV23 dose and a dose 2 of PPSV23 administered 5 years after dose 1 of PPSV23 and at least 8 weeks after a dose of PCV13
Chronic liver disease, alcoholism:
Age 6–18 years
No history of PPSV23: 1 dose PPSV23 (at least 8 weeks after any prior PCV13 dose)
*Incomplete series = Not having received all doses in either the recommended series or an age-appropriate catch-up series. See Tables 8, 9, and 11 in the ACIP pneumococcal vaccine recommendations (www.cdc.gov/mmwr/pdf/rr/rr5911.pdfpdf icon) for complete schedule details.
For contraindications and precautions to Pneumococcal conjugate (PCV13), see PCV13 Appendix and Pneumococcal polysaccharide (PPSV23), see PPSV23 Appendix
Poliovirus vaccination
(minimum age: 6 weeks)
4-dose series at ages 2, 4, 6–18 months, 4–6 years; administer the final dose on or after age 4 years and at least 6 months after the previous dose.
4 or more doses of IPV can be administered before age 4 years when a combination vaccine containing IPV is used. However, a dose is still recommended on or after age 4 years and at least 6 months after the previous dose.
In the first 6 months of life, use minimum ages and intervals only for travel to a polio-endemic region or during an outbreak.
IPV is not routinely recommended for U.S. residents age 18 years or older.
Series containing oral polio vaccine (OPV), either mixed OPV-IPV or OPV-only series:
For contraindications and precautions to Rotavirus (RV) [RV1 (Rotarix®), RV5 (RotaTeq®)], see Rotavirus Appendix
Tetanus, diphtheria, and pertussis (Tdap) vaccination
(minimum age: 11 years for routine vaccination, 7 years for catch-up vaccination)
Adolescents age 11–12 years: 1 dose Tdap
Pregnancy: 1 dose Tdap during each pregnancy, preferably in early part of gestational weeks 27–36.
Tdap may be administered regardless of the interval since the last tetanus- and diphtheria-toxoid-containing vaccine.
Adolescents age 13–18 years who have not received Tdap: 1 dose Tdap, then Td or Tdap booster every 10 years
Persons age 7–18 years not fully vaccinated* with DTaP: 1 dose Tdap as part of the catch-up series (preferably the first dose); if additional doses are needed, use Td or Tdap.
Tdap administered at age 7–10 years
Children age 7–9 years who receive Tdap should receive the routine Tdap dose at age 11–12 years.
Children age 10 years who receive Tdap do not need the routine Tdap dose at age 11–12 years.
DTaP inadvertently administered on or after age 7 years:
Children age 7–9 years: DTaP may count as part of catch-up series. Administer routine Tdap dose at age 11–12 years.
Children age 10–18 years: Count dose of DTaP as the adolescent Tdap booster.
*Fully vaccinated = 5 valid doses of DTaP OR 4 valid doses of DTaP if dose 4 was administered at age 4 years or older.
Wound management in persons age 7 years or older with history of 3 or more doses of tetanus-toxoid-containing vaccine: For clean and minor wounds, administer Tdap or Td if more than 10 years since last dose of tetanus-toxoid-containing vaccine; for all other wounds, administer Tdap or Td if more than 5 years since last dose of tetanus-toxoid-containing vaccine. Tdap is preferred for persons age 11 years or older who have not previously received Tdap or whose Tdap history is unknown. If a tetanus-toxoid-containing vaccine is indicated for a pregnant adolescent, use Tdap.
For contraindications and precautions to Tetanus, diphtheria, and acellular pertussis (Tdap) and Tetanus, diphtheria (Td), see Tdap and Td Appendix
Varicella vaccination
(minimum age: 12 months)
2-dose series at age 12–15 months, 4–6 years
VAR or MMRV may be administered*
Dose 2 may be administered as early as 3 months after dose 1 (a dose inadvertently administered after at least 4weeks may be counted as valid)
*Note: For dose 1 in children age 12–47 months, it is recommended to administer MMR and varicella vaccines separately. MMRV may be used if parents or caregivers express a preference.
Links with this icon indicate that you are leaving the CDC website.
The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
You will be subject to the destination website's privacy policy when you follow the link.
CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.
For more information on CDC's web notification policies, see Website Disclaimers.